Zacks Investment Research
01 Oct 2026, 14:50 UTC · 1h ago
Verdict
Headline leans bullish. We score LLY +0.80 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Eli Lilly's Phase 3 data for retatrutide showed 34.9% of patients on the highest dose lost at least 25% of their body weight.
Newunveiled at the 2026 EASD annual meeting
So whatSuperior weight loss efficacy supports a 'best-in-class' valuation, potentially expanding Lilly's peak sales estimates for the 2030 horizon.
More positive than 93% of claims this week
Continue reading
5 related stories
More positive than 89% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Novo Nordisk presented real-world data indicating Ozempic is associated with a 6% lower risk of major cardiovascular events than Lilly's Mounjaro.
Newunveiled at the 2026 EASD annual meeting
So whatA cardiovascular advantage could shift payer preference and formulary positioning in the next 12 months, offsetting efficacy losses.
More positive than 79% of claims this week
Lilly's new combination drug, EloraTZP, delivered up to 23.3% weight loss in patients with obesity and type 2 diabetes.
Newunveiled at the 2026 EASD annual meeting
So whatExpanding the portfolio into combined therapies diversifies revenue streams beyond single-molecule GLP-1s by the next print.
More positive than 67% of claims this week
The global market for anti-obesity medications is projected to exceed $100 billion by 2030.
Priced inlong-term projection
So whatThe scale of this TAM justifies the high P/E multiples currently assigned to LLY and NVO.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
Presented strong Phase 3 data for retatrutide and EloraTZP, showing significant weight loss efficacy.
More positive than 83% of ticker scores this week
Provided real-world data suggesting lower cardiovascular risk for Ozempic and is expanding its oral drug pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
8h ago
−0.8%
Price is moving against the score
$1148.35 vs $1157.08 close before publication (Sep 30) · not market-adjusted
LLY chart →
